Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Code of Conduct [a]
CC transcript
EyePoint Pharmaceuticals, Inc. (EYPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/02/2023 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments – Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy on track with enrollment completion anticipated in 4Q 2023 – – Net product revenues for Full Year 2022 of $39.9 million, a 13.0% increase versus Full Year 2021 of $35.3 million – – $144.6M of cash and investments at December 31, 2022 with cash runway projected into 2H 2024 – – Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., March 2, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve..."
08/03/2022 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments – First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists 2022 Annual Meeting – – Announced in conjunction with OcuMension Therapeutics, approval of New Drug Application by China’s National Medical Products Administration for YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye – – Net product revenue of $11.3 million in Q2 2022; a 30% increase from Q2 2021 – – Management to host a conference call and webcast today at 8:30 a.m...."
05/04/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments – Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists –"
08/04/2021 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments Positive 30-Day Safety Data Reported for EYP-1901 DAVIO study for the potential treatment of wet AMD; study remains on track for initial readout in Q4 2021"
05/05/2021 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments - EYP-1901 DAVIO study for the potential treatment of wet AMD dosed first patient in January; study remains on track for initial data in Q4 2021"
03/04/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments - Total revenues of $15.7 million and net product revenues of $5.8 million -"
08/05/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
03/05/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress – U.S. commercial launch trajectory for DEXYCU® and YUTIQ® gains momentum with strong customer order growth over Q2 -"
08/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : August 7, 2019 EyePoint Pharmaceuticals, Inc. Delaware 000-51122 26-2774444 480 Pleasant Street Watertown, MA 02472 926-5000 Registrant's Telephone Number, Including Area Code Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communication pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communication pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communi...",
"EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress"
05/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : May 8, 2019 EyePoint Pharmaceuticals, Inc. Delaware 000-51122 26-2774444 480 Pleasant Street Watertown, MA 02472 926-5000 Registrant's Telephone Number, Including Area Code",
"EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress"
11/07/2016 8-K Quarterly results
Docs: "pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline"
09/12/2016 8-K Form 8-K - Current report
09/09/2015 8-K Form 8-K - Current report
05/08/2015 8-K Form 8-K - Current report
02/05/2015 8-K Form 8-K - Current report
11/07/2014 8-K Form 8-K - Current report
09/09/2014 8-K Form 8-K - Current report
05/13/2014 8-K Form 8-K - Current report
02/07/2014 8-K Form 8-K - Current report
11/12/2013 8-K Form 8-K - Current report
09/25/2013 8-K Form 8-K - Current report
05/13/2013 8-K Form 8-K - Current report
02/06/2013 8-K Form 8-K - Current report
11/08/2012 8-K Form 8-K - Current report
09/24/2012 8-K Form 8-K - Current report
05/09/2012 8-K Form 8-K - Current report
02/08/2012 8-K Form 8-K - Current report
11/07/2011 8-K Form 8-K - Current report
09/12/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy